TThytech
Thytech is a Madrid-based biotech spin-off of the Gregorio Marañón Health Research Institute (IISGM) developing cell therapies based on regulatory T cells obtained from thymic tissue (thyTregs), a novel cell source pioneered by its founders' Immunoregulation Laboratory. Its lead programme targets prevention of graft rejection in pediatric heart transplantation — it performed the world's first-in-human thyTreg therapy in a transplanted infant (published in the Journal of Experimental Medicine) — with further applications in autoimmune and inflammatory diseases. Founded in 2022, it raised a ~€350K seed round led by Banco Sabadell's BStartup Health, later added Farmalider as industrial partner via a capital increase (June 2026), and has secured over €2M in public funding from Spain's State Research Agency and CDTI.
Founders
Global models 5
O
S
Q
GIn the same niche 67 others
See all in the Start-ups Map →
Notes: Most funded first
Investors 3
Open as list →
Funding rounds 2
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2026-06-16 | No stage disclosed | — | Farmalider |
| 2022-04-08 | Pre-seed | €350K |
BStartup (Banco Sabadell)
+1 more
|